These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 11483877)
1. Electropharmacologic effects of a new phosphodiesterase III inhibitor, toborinone (OPC-18790), assessed in an in vivo canine model. Sugiyama A; Satoh Y; Hashimoto K J Cardiovasc Pharmacol; 2001 Aug; 38(2):268-77. PubMed ID: 11483877 [TBL] [Abstract][Full Text] [Related]
2. Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs. Sugiyama A; Satoh Y; Shiina H; Takahara A; Yoneyama M; Hashimoto K J Cardiovasc Pharmacol; 2001 Dec; 38(6):940-6. PubMed ID: 11707698 [TBL] [Abstract][Full Text] [Related]
3. Acute effects of toborinone on vascular capacitance and conductance in experimental heart failure. Semeniuk LM; Belenkie I; Tyberg JV Circulation; 1998 Jul; 98(1):58-63. PubMed ID: 9665061 [TBL] [Abstract][Full Text] [Related]
4. Cardiohemodynamic and electrophysiological effects of a selective EP4 receptor agonist ONO--AE1--329 in the halothane-anesthetized dogs. Nomura H; Nakamura Y; Cao X; Honda A; Katagi J; Ohara H; Izumi-Nakaseko H; Satoh Y; Ando K; Sugiyama A Eur J Pharmacol; 2015 Aug; 761():217-25. PubMed ID: 26073024 [TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of OPC-8490 in human ventricular myocardium. Focaccio A; Peeters G; Movsesian M; Roden R; Eki Y; Krall J; Bristow MR Circulation; 1996 Feb; 93(4):817-25. PubMed ID: 8641012 [TBL] [Abstract][Full Text] [Related]
6. In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol. Sugiyama A; Satoh Y; Hashimoto K Toxicol Appl Pharmacol; 2001 Jun; 173(2):120-8. PubMed ID: 11384214 [TBL] [Abstract][Full Text] [Related]
7. Positive inotropic and chronotropic effects of toborinone and its electrophysiological properties in the isolated hearts of rabbits and guinea-pigs. Takase H; Orito K; Mori T; Fujiki H; Sekiguchi K; Tominaga M; Iijima T Arzneimittelforschung; 1996 Jun; 46(6):579-86. PubMed ID: 8767347 [TBL] [Abstract][Full Text] [Related]
8. Species-dependent pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 58993 and WIN 62005. Dundore RL; Pagani ED; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ J Cardiovasc Pharmacol; 1995 Jan; 25(1):14-21. PubMed ID: 7723343 [TBL] [Abstract][Full Text] [Related]
9. Effects of toborinone on myocardial oxygen consumption in pacing-induced heart failure dogs. Itoh S; Mori T; Fujiki H; Tominaga M Arzneimittelforschung; 1996 Dec; 46(12):1105-9. PubMed ID: 9006782 [TBL] [Abstract][Full Text] [Related]
10. Effects of a new cardiotonic phosphodiesterase III inhibitor, olprinone, on cardiohemodynamics and plasma hormones in conscious pigs with heart failure. Adachi H; Tanaka H J Cardiovasc Pharmacol; 1997 Jun; 29(6):763-71. PubMed ID: 9234657 [TBL] [Abstract][Full Text] [Related]
11. Effects of toborinone (OPC-18790), a new positive inotropic agent, on action potential in guinea pig sinoatrial node: compared with milrinone and E-4031. Orito K; Takase H; Fujiki H; Mori T Jpn J Pharmacol; 1996 Sep; 72(1):79-82. PubMed ID: 8902604 [TBL] [Abstract][Full Text] [Related]
12. [Phosphodiesterase III inhibitor--characteristics, mechanisms of action, pharmacokinetics, indications, contraindications, clinical trials, and side effects]. Sato N Nihon Rinsho; 2007 May; 65 Suppl 5():43-8. PubMed ID: 17571364 [No Abstract] [Full Text] [Related]
13. Inhibition of cyclic AMP phosphodiesterase activity and myocardial contractility: effects of cilostamide, a novel PDE inhibitor, and methylsiobutylxanthine on rabbit and canine ventricular muscle. Endoh M; Satoh K; Yamashita S Eur J Pharmacol; 1980 Aug; 66(1):43-52. PubMed ID: 6157546 [No Abstract] [Full Text] [Related]
14. Effect of phosphodiesterase III inhibitor on contractility, afterload, and vascular capacitance during right heart bypass preparation. Tanoue Y; Morita S; Nagano I; Ochiai Y; Tominaga R; Kawachi Y; Yasui H Jpn J Thorac Cardiovasc Surg; 2001 Oct; 49(10):607-13. PubMed ID: 11692586 [TBL] [Abstract][Full Text] [Related]
15. Differential sensitivity to cardiotonic drugs of cyclic AMP phosphodiesterases isolated from canine ventricular and sinoatrial-enriched tissues. Komas N; Lugnier C; Le Bec A; Serradeil-Le Gal C; Barthélémy G; Stoclet JC J Cardiovasc Pharmacol; 1989 Aug; 14(2):213-20. PubMed ID: 2476593 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular actions of OPC-18790: a novel positive inotropic agent with little chronotropic action. Hosokawa T; Mori T; Fujiki H; Kinoshita S; Takemoto K; Imaizumi T; Noda T; Ohura M; Tominaga M; Yabuuchi Y Heart Vessels; 1992; 7(2):66-75. PubMed ID: 1328145 [TBL] [Abstract][Full Text] [Related]
17. QT-prolonging effects of sparfloxacin, a fluoroquinolone antibiotic, assessed in the in vivo canine model with monophasic action potential monitoring. Satoh Y; Sugiyama A; Chiba K; Tamura K; Hashimoto K J Cardiovasc Pharmacol; 2000 Oct; 36(4):510-5. PubMed ID: 11026654 [TBL] [Abstract][Full Text] [Related]
18. Effects of phosphodiesterase III inhibition on length-dependent regulation of myocardial function in coronary surgery patients. De Hert SG; ten Broecke PW; Mertens E; Rodrigus IE; Stockman BA Br J Anaesth; 2002 Jun; 88(6):779-84. PubMed ID: 12173193 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of the combination of OPC-18790 and dopamine in halothane-anesthetized dogs. Itoh S; Mori T; Yoshida K; Fujiki H; Tominaga M; Yabuuchi Y Jpn J Pharmacol; 1995 Nov; 69(3):229-37. PubMed ID: 8699631 [TBL] [Abstract][Full Text] [Related]
20. In vivo evidence of positive inotropism of EMD 57033 through calcium sensitization. Haeusler G; Jonas R; Minck KO; Schliep HJ; Schelling P; Weygandt H; Lues I J Cardiovasc Pharmacol; 1997 May; 29(5):647-55. PubMed ID: 9213208 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]